Overview

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Semaxinib